Harvard Business Review

JUNE 21, 2013

Given the forecasts of uncertain global economic growth, we might expect companies to hold off from hiring new employees and to limit whatever international hiring they do to emerging markets. If, in addition, companies are managing their underperformers out poorly, the costs rise even further. Global business Talent management'

Telecommunications 9

Telecommunications Health Care Talent Management Biotechnology 9

Harvard Business Review

FEBRUARY 22, 2013

Having observed management teams for decades as a mutual fund and portfolio manager, I have watched numerous companies vanish after a disastrous launch of a product or service. Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. What do you do next?

Productivity 8

Productivity Products Biotechnology IPO 8

Harvard Business Review

APRIL 27, 2012

These are all pretty common assertions in modern business/tech journalism and management literature. but the emerging markets boom has generally been more about catching up than exploiting cutting-edge technology.). Business models are being transformed, lives are being upended, vast new horizons of possibility opened up.

Stephenson 16

Stephenson Innovation Biotechnology eBook 16

Harvard Business Review

MARCH 13, 2012

When I was teaching at Peking University, for example, one of my fellow professors monitored an experiment in which the Chinese government gave local villagers the rights to manage a forest. And of course that's true — but the commodities market has been booming only in recent years, and the bank's track record is long and impressive.

Biotechnology 10

Biotechnology Real Estate Tourism Banking 10

Harvard Business Review

AUGUST 17, 2015

There was a spike in the 2000s when Venezuela began to provide petroleum at deeply discounted market prices, and that peaked just before the 2008-09 financial crisis. It is probably the best, most well-trained workforce at the cheapest labor-market price that any international investor could find anywhere in the world.

Biotechnology 8

Biotechnology Tourism Human Capital Pharmaceuticals 8

Harvard Business Review

JUNE 3, 2013

What kind of signal did this choice send to P&G''s top managers? Is the problem that P&G produces outstanding specialists in marketing but not general managers who can run the business? Using data from the 2012 survey, we also found that boards gave their companies'' very poor grades on talent management.

Succession 8

Succession Telecommunications Biotechnology Real Estate 8

Strategy Driven

NOVEMBER 18, 2019

This increased the need for care items for the elderly and there are plenty of gaps in the market for the healthcare sector. There have also been great leaps forward in biotechnology and even people without investment experience in the industry can find a niche sector to become involved in.

Health Care 67

Health Care Biotechnology Energy Insurance 67

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. French pharmaceutical company Sanofi recently acquired Boston-based Genzyme to tap into America's intellectual capital in biotechnology.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

JULY 16, 2013

And 43% cited technology expertise, HR-talent management, international-global expertise, and succession planning as the skills missing most on their boards. The industry with the greatest skills gap was IT & telecommunications, whose boards are in serious need of international-global expertise and HR-talent management.

Telecommunications 8

Telecommunications Biotechnology Health Care Real Estate 8

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines. It is commonly believed that emerging market companies tap Western R&D talent in order to 'move up the value chain.'

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Risk and outcomes, as the scenario plays out, will be managed by predictive models, which are powered by machine learning algorithms that will improve their accuracy rates over time.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

OCTOBER 22, 2013

In order to do this, your company needs a process to source radical ideas that can catapult your business to new heights, open up new markets, or bring in completely unfamiliar profit streams. But in today’s ever-connected world, finding radical ideas seems to be getting tougher for companies. Use Convergence Thinking.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

FEBRUARY 19, 2015

Or pay a freelance consultant to do market research? Kate had had a taste of entrepreneurial life — she was on the management team of ArtusLabs, the North Carolina-based software company that was bought by PerkinElmer in 2011 — and knew how “exciting it was to work at a start-up.” Patch weak spots.

Project 8

Project Outsourcing Learning-by-Doing Commitment 8

Harvard Business Review

FEBRUARY 3, 2015

By managing the three key properties of networks that either propel you forward or hold you back—breadth, connectivity, and dynamism—you can develop a stronger network and use it as an essential leadership tool. This article will show you how to reinvent your network, by managing these three critical dimensions.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

MARCH 17, 2014

An estimated 250 funds are actively raising capital in a market that the Global Impact Investing Network estimates at $25 billion. In impact investing, we need to find a way to place that same premium on social impact by valuing the public good being created – just like we do in early stage R&D in science, IT, health, and biotechnology.

Development 9

Development Microfinance Biotechnology Exit Strategy 9

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. If you’re in the upper right quadrant — or in the top 10 most uncertain industries as shown in the Table — you require greater innovation management skills than industries in the other quadrants or in the bottom 10.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

JUNE 12, 2012

trillion in government support for seven "strategic emerging industries," including alternative energy, biotechnology, next-gen IT, high-end manufacturing equipment, and advanced materials. A decade from now we may look back at China's 12th Five-Year Plan as the seminal document of the early 21st century. It pledges $1.5

First-mover Advantage 9

First-mover Advantage GDP Technology Biotechnology 9

Harvard Business Review

NOVEMBER 9, 2016

While it’s understandable that stock and currency markets would react this way to the outcome of the election, I believe that it’s somewhat of an overreaction. Local leaders managed this by enhancing the value of the steel industry — not reducing it. president. Four out of five avocados sold in the U.S.

Cooper 14

Cooper Long-term Industry Health Care 14